Raj Parekh

Raj is a General Partner at Advent. He joined Advent in 2005 bringing over 20 years of experience in biomedical research and as an entrepreneur and investor.

After gaining an MA and DPhil from Oxford University, he pursued a successful academic career in molecular medicine before co-founding Oxford GlycoSciences (IPO on LSE and NASDAQ). Following its sale to UCB-Celltech, he became Chairman of Galapagos nv, a member of the Supervisory Board of the Novartis Venture Fund and a founding Director of Celldex Therapeutics.

Since joining Advent, Raj has been mainly involved in founding and supporting portfolio Companies that are involved in the discovery of new medicines. Raj has represented Advent on the Board of over 25 portfolio Companies including Avila Therapeutics, Amphista, CN Creative and EUSA Pharma.

Raj currently serves on the Board of several Advent portfolio Companies including Aleta, Arrakis, Artax, Aura BioSciences and Levicept.